MNPR Stock — Monopar Therapeutics Inc.: Cash, EV, Pipeline

What they do

Our Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Our radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of advanced cancers, that express urokinase plasminogen activator receptor (“uPAR”).

Source: 10-K FY2025 via SEC EDGAR

Share price

$71.27

Market cap

$483.0M

Cash

$105.1M

Enterprise value

$377.9M

Balance sheet

Cash	$105.1M
Debt	$0.0M
Net cash	$105.1M
Enterprise value	$377.9M
Basic shares	6.8M shares
Fully diluted shares	9.4M shares
Fully diluted market cap	$668.4M
Cash per share	$15.50
Quarterly burn	$3.2M
Cash runway	41.4 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-13.

Share structure

Common

6.7M

Pre-funded warrants

1.8M

Options

0.7M

RSUs

0.1M

Warrants

—

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

9.4M

Cap table as of 2026-07-31.

Price history

Loading MNPR daily closes…

Loading price history…

Next catalyst

MNPR-101-DFO*-89Zr · Jan 12 - Feb 23 in 8 wks · Phase 1 · Solid Tumor, Adult; Bladder Cancer; Urothelial Carcinoma

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23 in 8 wks	MNPR-101-DFO*-89Zr	Phase 1	Solid Tumor, Adult; Bladder Cancer; Urothelial Carcinoma	—
Feb 12 - Mar 26 in 13 wks	MNPR-101-PCTA-177Lu	Phase 1	Solid Tumor, Adult; Bladder Cancer; Urothelial Carcinoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ALXN1840

Phase 3 · Active Modality: small molecule

Aliases Tiomolybdate choline

Target copper

Partnerships Alexion Pharmaceuticals, Inc. (AstraZeneca subsidiary): exclusive license agreement (October 23, 2024) granting Monopar rights to ALXN1840; Alexion had previously completed the pivotal Phase 3 and terminated its own ALXN1840 program

Indications

Wilson disease (Phase 3)

Status note Once-daily oral investigational drug for Wilson disease. Alexion completed a pivotal Phase 3 trial, then terminated the program. Monopar licensed the program and initiated a rolling NDA submission on July 22, 2026.

MNPR-101-Zr

Phase 1 · Active Modality: radiopharmaceutical

Target uPAR

Partnerships Excel Diagnostics and Nuclear Oncology Center (EDNOC): collaboration; authorization received June 11, 2025 to conduct imaging studies

Indications

Advanced cancers (diagnostic imaging) (Phase 1)

Status note Humanized monoclonal antibody MNPR-101 conjugated with zirconium for PET imaging of uPAR-expressing tumors.

MNPR-101-Lu

Phase 1 · Active Modality: radiopharmaceutical

Target uPAR

Partnerships NorthStar: long-term non-exclusive master supply agreement (June 2024) for therapeutic radioisotope actinium-225; XOMA (US) LLC: non-exclusive license to humanization technology for MNPR-101

Indications

Advanced cancers (therapeutic) (Phase 1)

Status note Lutetium-labeled MNPR-101 radiopharmaceutical therapeutic targeting uPAR. FDA cleared the IND application on September 26, 2025 for a Phase 1 open-label, multicenter dosimetry and dose-escalation trial.

Per-asset detail extracted from the 10-Q filed 2026-07-31. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	MNPR-101-DFO*-89Zr
Lead indication	Solid Tumor, Adult
Lead phase	Phase 1
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06337084	Phase 1	Active, not recruiting	Sponsor	Monopar Therapeutics	—	Solid Tumor, Adult; Bladder Cancer; Urothelial Carcinoma	—
NCT06617169	Phase 1	Active, not recruiting	Sponsor	Monopar Therapeutics	—	Solid Tumor, Adult; Bladder Cancer; Urothelial Carcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Monopar Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RA Capital Management	667,207	no change	0.54%	2026-08-14
Deerfield Management	323,745	no change	0.31%	2026-08-14
ADAR1 Capital Management	217,595	-46,683	0.95%	2026-08-14
OrbiMed Advisors	157,423	+157,423	0.28%	2026-08-14
Vivo Capital	90,500	no change	0.77%	2026-08-14
Ikarian Capital	47,861	+47,861	0.73%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

MNPR — Monopar Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

MNPR — Monopar Therapeutics Inc.